44 results about "Agglutinin" patented technology

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The application discloses a fucose glycoprotein detection kit, a preparation method thereof and a fucose glycoprotein color developing method. First, a liquid sample is dropped on the surface of the kit, and the sample and test paper are infiltrated through a sample inlet. Under the action of transverse flow force, the sample flows to an observation window along a hydrophilic test paper. The glycoprotein containing alpha 1,2-fucose in the sample is combined with agglutinin 1, and the rest of the sample continues to flow to the next layer of test paper. Then, the glycoprotein containing alpha 1,3-fucose is combined with agglutinin 2, and the rest of the sample flows to the third layer and is combined with agglutinin 3 containing alpha 1,6-fucose glycoprotein. All the combined fucose glycoproteins are combined with agglutinin biotin through their antibodies, and horseradish peroxidase is used for labeling color development, so that quantitative detection of the fucose glycoprotein in the sample is realized. The method has important significance for studying the changes of different connection fucose glycoproteins in cells and body fluids in diseases.

To provide an osteoclast fusion inhibitor that is highly effective and has few side effects. [Solution] An osteoclast fusion inhibitor containing an anti-galectin-3 neutralizing antibody as an active ingredient.

Provided herein are methods and compositions for suppressing a foreign body reaction, such as an implant-associated inflammation in a subject, by using an anti-Galectin-3 antibody. Such methods and compositions can be used in various areas applications where an implant is introduced, such as in brain-computer interface (BCI).

The invention provides humanized monoclonal antibodies against Gal9, and method of using the antibodies to treat cancer, including combination therapy with antagonists of the PD-1 / PD-L1 immune checkpoint.

The invention relates to a preparation method and application of a probe based on wheat germ lectin. The probe is provided with a core-shell structure, and the core-shell structure is provided with a core and a shell wrapping the outer surface of the core. The core of the core-shell structure is Fe3O4 nanoparticles; the shell comprises a first cationic polymer layer, a gold nanoparticle layer, a second cationic polymer layer, a first quantum dot layer, a third cationic polymer layer, a second quantum dot layer and a wheat germ agglutinin layer which are sequentially coated from the outer surface of the core to the outside. The probe has relatively strong magnetic response capability, colorimetric signals, fluorescence signals and capability of capturing various virus glycoproteins; the MAuDQD-coated WGA-LFA method based on the probe provided by the invention is relatively wide in target detection object range, relatively high in detection sensitivity, relatively high in accuracy and relatively short in detection time.

Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

The invention discloses a multi-copy expression construction method of an insecticidal fusion peptide U10-MYRTX-Mri1a-GNA with bacteriostatic activity in pichia pastoris, which comprises the following steps: 1, carrying out reverse PCR (Polymerase Chain Reaction) on a plasmid pGAPZalpha A, introducing a Hind III restriction enzyme cutting site to obtain a plasmid pGAPZalpha A-Hind III, 2, constructing a fragment containing a U10-MYRTX-Mri1a gene, and 3, carrying out multi-copy expression on the fragment containing the U10-MYRTX-Mri1a gene to obtain the insecticidal fusion peptide U10-MYRTX-Mri1a gene. The method comprises the following steps: 1, constructing a U10-MYRTX-Mri1a gene fragment, 2, constructing a U10-MYRTX-Mri1a gene fragment, 3, introducing a GGGSAAA linker and a snowflake agglutinin (GNA)-6 * His label to the C end of the U10-MYRTX-Mri1a gene fragment, 4, constructing a multi-copy expression vector pGAPZalpha A-HindIII-Mira1-GNA * 3, 5, preparing a pichia pastoris competent cell X33, and 6, carrying out electrochemical conversion to obtain a genetically engineered bacterium X33-pGAPZalpha A-HindIII-Mira1-GNA * 3. According to the invention, a linearized plasmid is transferred to pichia pastoris X33, so that a genetically engineered bacterium for expressing the fusion peptide U10-MYRTX-Mri1a-GNA is obtained.

Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).

The invention discloses a kit for detecting plasma IgG glycosylation level and a detection method thereof, and relates to the technical field of biological detection.Plasma IgG is specifically captured through protein A, four biotinylation lectins are combined, sialylation, galactosylation, fucosylation and mannosylation levels of IgG can be synchronously and quantitatively detected, a standardized ELISA system is established, and the kit is used for detecting the plasma IgG glycosylation level. Operation is easy and convenient, repeatability is good, and the problem that multi-dimensional simultaneous detection cannot be achieved in the prior art is solved. The kit is low in cost, does not need complex instruments, is suitable for large-scale clinical popularization, and fills the market blank of commercial IgG glycosylation ELISA kits. Clinical samples of colorectal cancer prove that patients and healthy people can be effectively distinguished, in-vitro risk assessment can be realized by combining a column diagram model, the detection efficiency is excellent, and the method can be expanded to be applied to assessment and monitoring of various tumor and inflammation related diseases, and has high clinical value.

The invention relates to a double-probe detection kit for detecting escherichia coli O157: H7 and a preparation method of the double-probe detection kit, and belongs to the technical field of food safety. The double-probe detection kit consists of a magnetic separation probe reagent and a copper-manganese double-metal nano-enzyme probe reagent which are independently packaged. The magnetic separation probe reagent is a concanavalin agglutinin A modified magnetic bead, and is used for specifically binding escherichia coli O157: H7 in a meat product detection sample and carrying out separation and enrichment treatment; the bimetallic nano-enzyme probe reagent is copper-manganese bimetallic nano-enzyme modified by a nucleic acid aptamer, and is used for specifically combining with the escherichia coli O157: H7 subjected to separation and enrichment treatment and generating an escherichia coli O157: H7 concentration dependent colorimetric signal and a fluorescence signal. According to the invention, mutual verification is carried out between dual-mode signals, so that the accuracy of a detection result is improved; the detection time is within 1.5 h, and the method has good specificity for common type strains. The invention provides a design thought for the development of detection sensors for escherichia coli O157: H7 and other meat-derived pathogenic bacteria.

The present invention provides compositions used for the treatment and / or prevention of protein aggregation disorders. [Solution] Proteopathy encompasses a wide range of ailments, including neurodegenerative diseases (e.g., polyglutamine diseases such as huntingtin in Alzheimer's disease, Parkinson's disease, and Huntington's disease, and prion diseases); amyloidosis of other non-neuronal proteins (especially I1-antitrypsin, immunoglobulin light and heavy chains, lactadherin, apolipoprotein, gelzolin, lysozyme, fibrinogen, atrial natriuretic factor, keratin, lactoferrin, and β-2 microglobulin, etc.); sickle cell disease; cataracts; cystic fibrosis; retinitis pigmentosa; and nephrogenic diabetes insipidus. Administration of sulfatase inhibitors is generally suitable for treating and / or preventing protein toxicity associated with proteopathy. Therefore, the present invention provides compositions comprising sulfatase inhibitors for the treatment of proteopathy.

The present application relates to a kind of agglutinin joint targeting peptide modified nanosphere and its preparation method and application, belong to the biomedicine technical field.To solve the problem that the existing drug delivery system is difficult to have the integration of nasal brain barrier breakthrough, nasal long-term retention, brain lesion targeting, broad-spectrum drug loading and high biological stability, the present application provides a kind of agglutinin joint targeting peptide modified nanosphere, including polymer matrix core, biomimetic cell membrane shell and double-ligand functionalization surface crown layer in turn from inside to outside.The nanosphere of the present application can prolong the nasal retention time and efficiently penetrate the nasal mucosa barrier by relying on the synergistic effect of core-shell-crown three-layer structure, realize transnasal brain and lesion precise targeting, improve drug delivery efficiency and efficacy, and reduce toxic side effects.The nanosphere of the present application has a wide range of drug loading spectrum, suitable for the drug demand of various central nervous system diseases, and has excellent clinical transformation value and application prospect.

The invention belongs to the technical field of antivirus, and particularly discloses a siniperca chuatsi frog iridovirus oral composite vaccine and a preparation method thereof.The composite vaccine comprises an antigen core, a mucous membrane penetrating layer, a pH sensitive protective shell layer and a targeted modification layer, and the antigen core is formed by compounding a siniperca chuatsi frog iridovirus inactivated vaccine and an immunologic adjuvant; the mucous membrane penetrating layer is a pegylated chitosan-sodium alginate compound; the pH sensitive protective shell layer is a poly (beta-amino ester)-trehalose copolymer, and the targeted modification layer is wheat lectin. According to the siniperca chuatsi and frog iridovirus oral compound vaccine and the preparation method thereof, the technical problems that oral vaccines are easily degraded by digestive enzymes in aquatic animal bodies and the mucous membrane absorption efficiency is low are solved through the multi-layer structural design, the immune protection effect of the vaccines is remarkably improved, and the preparation method is simple and controllable and suitable for large-scale production.

Methods, systems, and kits are provided for standardizing lectin reagents and measuring galactose-deficient IgA1 (Gd-IgA1) as a biomarker for IgA nephropathy. The invention includes a method for standardizing test batches of lectin reagents by comparing binding activity to reference batches using calibration standards, with acceptance criteria based on analytical recovery within thresholds. A stabilized reference standard comprising enzymatically modified or recombinantly produced Gd-IgA1 exhibits parallelism with natural serum samples and enables reproducible quantification across runs. The invention further provides a lectin-based ELISA assay kit for quantitative measurement of Gd-IgA1 in biological samples, particularly serum, using standardized N-acetylgalactosamine (GalNAc)-specific lectins such as biotinylated Helix pomatia agglutinin (HPA) or Helix aspersa agglutinin (HAA). Clinical applications include diagnosing IgA nephropathy, risk stratification, monitoring disease progression, assessing treatment response, and screening kidney transplant donors. The standardization methodology is broadly applicable to validating binding reagents for detecting diverse biomarkers, peptides, and proteins in diagnostic assays.

The present invention provides a pharmaceutical composition capable of accelerating the regeneration rate of damaged areas in nerves. [Solution] A pharmaceutical composition for promoting nerve regeneration, comprising (A) a hyaluronic acid derivative into which a cholesteryl group has been introduced, (B) one or more factors selected from the group consisting of secretory sialic acid-binding immunoglobulin-like lectin-9 and monocyte chemotactic factor-1, and (C) a cell adhesion material derived from collagen; the average molecular weight of the hyaluronic acid derivative into which the cholesteryl group has been introduced is 5,000 or more and 50,000 or less; and a method for promoting nerve regeneration, comprising contacting any of the pharmaceutical compositions with a damaged site in nerve tissue.

This invention relates to a comprehensive evaluation method for the quality of Pinellia ternata and a method for constructing a fingerprint spectrum of Pinellia ternata. The method includes: processing Pinellia ternata to obtain a test solution; preparing a reference solution containing guanosine, phenylalanine, VGTNY, tryptophan, LFSG, apigenin-6-C-arabinose-8-C-galactoside, PWVPG, NIPF, and VIYGPSVF; injecting the test solution and the reference solution separately into a liquid chromatography-mass spectrometry (LC-MS) instrument, and obtaining the fingerprint spectrum of the Pinellia ternata using LC-MS. A method for determining the content of toxic components calcium oxalate needle crystals and lectin protein is also established. The comprehensive evaluation method for the quality of Pinellia ternata provided by this invention comprehensively improves the evaluation standards for Pinellia ternata, ensuring the effectiveness and safety of Pinellia ternata in clinical use.

The invention relates to a lectin chip for predicting colorectal cancer immunotherapy sensitivity and a preparation method and application thereof, and belongs to the technical field of tumor therapy. According to the chip disclosed by the invention, three specific agglutinin probes are fixed on the surface of a solid-phase carrier in a dot matrix manner, and combined detection of at least three carbohydrate chains in human serum is realized by coating three specific agglutinin probes; the solid-phase carrier is a 14-hole three-dimensional modified glass slide and is used for fixing specific lectin as a probe; and the three specific lectin probes are respectively PHA-E, SNA-I and SSA. The lectin chip can be used for predicting colorectal cancer immunotherapy sensitivity.

The present application relates to the field of food technology, and specifically discloses a composition for reducing gastroesophageal reflux in individuals, a preparation method and application thereof. The composition for reducing gastroesophageal reflux in individuals comprises lactadherin, medium-long chain triglyceride, human milk oligosaccharide and immunoglobulin G. The present application constructs a multi-target synergistic intervention mechanism combining physical protection, secretion regulation and tissue repair through the compounding of four core components, which can comprehensively block the occurrence and development of gastroesophageal reflux. Lactadherin constructs a physical barrier to reduce the risk of reflux dynamics from the source; MLCT precisely regulates gastric acid secretion, reducing chemical stimulation; HMO compound IgG strengthens the mucosal immune barrier and promotes damage repair. The above composition is applied to products for reducing gastroesophageal reflux in individuals, and multi-target synergistic effect is achieved, realizing the whole-chain closed-loop intervention from prevention, relief to repair, and significantly improving the clinical improvement effect.

The invention discloses application of carp roe lectin rCcFEL2 in preparation of a carp culture feed additive. The carp roe lectin rCcFEL2 has dual effects in improving disease resistance and growth performance of carps. The antibacterial function and the growth regulation effect of the carp roe lectin rCcFEL2 are systematically clarified for the first time, and the research blank of the lectin in antibacterial and immunological enhancement application of aquatic products is filled. An in-vitro antibacterial experiment proves that the carp roe lectin rCcFEL2 shows remarkable antibacterial activity on various common gram-negative bacteria and gram-positive bacteria in aquatic products, and is wide in antibacterial spectrum and stable in action effect; in-vivo challenge tests further show that the carp roe lectin rCcFEL2 can significantly enhance the disease-resistant defense capability of carp bodies and ovaries, effectively reduce the bacterial load in immune tissues infected by pathogenic bacteria, actively regulate the growth performance of carps and promote healthy growth of the bodies.

The invention relates to chimeric influenza vaccines. The present invention relates to a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more stem domain sequences fused to one or more globular head domain sequences, each of which has at least 60% homology with a stem domain common sequence of HA (H1 HA) subtype and / or H5 HA (H5 HA) subtype, the one or more globular head domain sequences each have at least 60% homology with a globular head domain common sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

The invention discloses concanavalin A-like agglutinin / glucanase structural domain protein FvCLG and application thereof in improving the yield of fusarium venanii hypha protein, and belongs to the fields of genetic engineering technology and food biotechnology. Compared with a wild type strain, the fusarium venanii FG31 has the advantages that the FvCLG gene on a genome is deleted, ethanol is not generated in a fermentation tank for 72 hours, and the protein content is obviously increased (as high as 61.34%) and is increased by 22.41% compared with the wild type strain. Meanwhile, when the FG31 strain is fermented, the sugar consumption is obviously reduced, the conversion rate from glucose to biomass and the conversion rate from glucose to protein are respectively improved by 44.02% and 76.41%, the utilization rate of a substrate is obviously improved, the loss of a carbon source is reduced, and the production cost is reduced. The fusarium venanii can be used for further developing genetic engineering modification work to cultivate a fusarium venanii strain with high protein content.

The invention provides a lysis buffer for targeted removal of red blood cells, a red blood cell lysis method and application thereof, and belongs to the technical field of red blood cell lysis. The lysate consists of a plasmodium merozoite extract, soybean plant hemagglutinin and a liquid-based cell preservation solution, wherein the liquid-based cell preservation solution is an aqueous solution containing glycyrrhizic acid, disodium ethylene diamine tetraacetate, disodium hydrogen phosphate, sodium chloride, potassium chloride and monopotassium phosphate. According to the method disclosed by the invention, the plasmodium merozoite extract and the soybean plant hemagglutinin are combined to quickly degrade protein and lipid which are key components of an erythrocyte membrane and destroy the integrity of a membrane structure, so that erythrocyte rupture is finally caused, and no adverse effect is caused on visible components such as other cells while the erythrocyte is efficiently and quickly removed.

The invention discloses a magnetic hydrothermal carbon material reversely wrapped by an unmarked cell membrane as well as a preparation method and application of the magnetic hydrothermal carbon material, magnetic carbon nanospheres are prepared by a hydrothermal method, and then carboxyl groups on the surfaces of the magnetic carbon nanospheres and residual amino groups of lectin such as concanavalin A are subjected to amide condensation, so that lectinized hydrothermal magnetic carbon nanospheres are obtained. Finally, agglutination reaction can be carried out on agglutinin and carbohydrate chains on the outer surface of the cell membrane, so that the cell membrane is wrapped from inside to outside. The biomimetic material can screen drugs acting on the inner side of a cell membrane, does not need to label the cell membrane, can reduce damage to membrane protein, provides a new technical means for deeply exploring lead compounds in natural products, and promotes development of traditional Chinese medicine anti-osteoporosis drugs. According to the invention, two novel potential anti-osteoporosis components targeting the inner surface of an osteoblast cell membrane in herba epimedii are successfully found.

The present application discloses a dark striped pufferfish L-type agglutinin VIP36, the amino acid sequence of which is shown as SEQ ID NO. 1, and the coding gene of which is shown as SEQ ID NO. 2. The present application also discloses the application of the dark striped pufferfish L-type agglutinin VIP36 in the preparation of a preparation with the efficacy of inhibiting Staphylococcus aureus, Vibrio parahaemolyticus, Aeromonas hydrophila and Vibrio harveyi. The present application firstly clones the coding gene of the dark striped pufferfish L-type agglutinin VIP36, constructs a prokaryotic expression vector of the dark striped pufferfish L-type agglutinin VIP36 and develops a recombinant protein; studies the use of the VIP36 recombinant protein in the immune defense function of the dark striped pufferfish, and the immune defense function includes regulating the homeostasis and health of the body, and the present application provides a theoretical basis for preventing diseases caused by pathogenic bacteria and a theoretical guidance for the healthy breeding of the dark striped pufferfish.

The present application relates to edible mushroom pest control technical field, especially a kind of edible mushroom anti-mite agglutinin protein PoLec2 and its coding gene and application, the protein is any one in the following A1, A2 or A3: A1) the protein with the amino acid sequence as shown in SEQ ID NO:1;A2) the amino acid sequence as shown in SEQ ID NO:1 is substituted and / or deleted and / or added by one or several amino acid residues, and the protein with same function;A3) the fusion protein obtained by connecting label at the N terminal of A1 or A2 or / and C terminal.The edible mushroom insect resistance related protein PoLec2 and its coding gene of the present application can be used to regulate the insect resistance of edible mushroom, edible mushroom variety breeding and genetic improvement.

1. Name of the product in this design: Packaging box (Galactosyllectomycin antibody reagent color box). 2. Purpose of this design: For use in packaging boxes. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.